Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.46 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.46 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL6419228 | 0.97 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL307009 | 0.97 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL28092959 | 0.97 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL307008 | 0.97 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL7717425 | 0.97 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL8023215 | 0.97 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL8074635 | 0.97 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL3655651 | 0.95 | GLRA1 (0.50) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL31453285 | 0.92 | GRIK1 (0.54) | GRIK1GRIK2GRM1GRM2GSR | |
| Aspartic Acid SCHEMBL21631741 | 0.92 | GRIK1 (0.54) | GRIK1GRIK2GRM1GRM2GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3216782-B1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) | 2021-06-02 | — | — | EP | claimed |
| US-20210122705-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) | 2021-04-29 | — | — | US | claimed |
| US-20180370903-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA - NÚCLEO DE PESQUISAS APLICADAS LTDA. (BR) | 2018-12-27 | — | — | US | claimed |
| EP-3216782-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA - Núcleo De Pesquisas Aplicadas LTDA. (BR) | 2017-09-13 | — | — | EP | claimed |
| CN-115244074-A | System for determining the underlying cause of anemia | 奎斯特诊断投资有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-3216782-B1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) | 2021-06-02 | — | — | EP | disclosed |
| US-20210122705-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) | 2021-04-29 | — | — | US | disclosed |
| US-10913705-B2 | Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof | NPA—NÚCLEO DE PESQUISAS APLICADAS LTDA (BR) | 2021-02-09 | — | — | US | disclosed |
| US-20180370903-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA - NÚCLEO DE PESQUISAS APLICADAS LTDA. (BR) | 2018-12-27 | — | — | US | disclosed |
| EP-3216782-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | NPA - Núcleo De Pesquisas Aplicadas LTDA. (BR) | 2017-09-13 | — | — | EP | disclosed |
| US-8425956-B2 | Mixed amino acid/mineral compounds having improved solubility | ALBION INTERNATIONAL, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120022162-A1 | Mixed Amino Acid/Mineral Compounds Having Improved Solubility | ALBION INTERNATIONAL INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8007846-B2 | Mixed amino acid/mineral compounds having improved solubility | ALBION INTERNATIONAL, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1976399-A2 | MIXED AMINO ACID/MINERAL COMPOUNDS HAVING IMPROVED SOLUBILITY | Albion Advanced Nutrition (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007084932-A2 | MIXED AMINO ACID/MINERAL COMPOUNDS HAVING IMPROVED SOLUBILITY | ALBION ADVANCED NUTRITION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070172551-A1 | MIXED AMINO ACID/MINERAL COMPOUNDS HAVING IMPROVED SOLUBILITY | ALBION ADVANCED NUTRITION (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913705-B2 | Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof | HAMP, FECH, TFRC | GLRA1 735/4885SLC6A9 185/4885OR51E2 680/4885 |
| US-20210122705-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | HAMP, FECH, TFRC | GLRA1 735/4885SLC6A9 185/4885OR51E2 680/4885 |
| US-20180370903-A1 | IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF | HAMP, FECH, TFRC | GLRA1 735/4885SLC6A9 185/4885OR51E2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.